Extrapyramidal symptoms were evaluated using the Simpson-Angus scale (Simpson and Angus 1979), Barnes Akathisia scale (Barnes 1989), and abnormal involuntary movement scale (AIMS) (National Institute of Mental Health 1976b).
5), the mean Barnes Akathisia Scale index score was 0.
The safety and efficacy of intramuscular ziprasidone were evaluated by using the following instruments: Behavioral Activity Rating Scale (BARS) (responders were defined a priori as having a [greater than or equal to] 2-point reduction in BARS score); Clinical Global Impressions, severity of illness (CGI-S) and global improvement (CGI-I) scales; Positive and Negative Syndrome Scale (PANSS); Barnes Akathisia Scale (BAS); and Simpson-Angus Scale (SAS) (4).
Additionally, iloperidone also had a similar akathisia profile to placebo, whereas ziprasidone was associated with a significant worsening of akathisia versus placebo on the Barnes Akathisia Scale (BAS), with 26 percent of patients experiencing a worsening of akathisia.
minimal drug-induced akathisia compared with clinically significant akathisia experienced by risperidone patients (scores on the Barnes Akathisia Scale, where a score of 0 represents no drug-induced akathisia, decreased from 1.